Zacks Research Downgrades Amneal Pharmaceuticals (NASDAQ:AMRX) to Hold

Amneal Pharmaceuticals (NASDAQ:AMRX) was downgraded by investment analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research report issued on Monday,Zacks.com reports.

A number of other brokerages also recently issued reports on AMRX. Barclays began coverage on Amneal Pharmaceuticals in a research report on Monday, December 8th. They set an “overweight” rating and a $15.00 price target on the stock. Truist Financial increased their price target on Amneal Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research report on Wednesday, January 21st. Five research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, Amneal Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $14.20.

Amneal Pharmaceuticals Stock Down 0.2%

Amneal Pharmaceuticals stock opened at $12.32 on Monday. The firm has a market cap of $3.88 billion, a price-to-earnings ratio of 53.57 and a beta of 1.32. The business’s 50-day moving average price is $13.42 and its 200 day moving average price is $12.32. Amneal Pharmaceuticals has a 52 week low of $6.68 and a 52 week high of $15.42.

Institutional Investors Weigh In On Amneal Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Spire Wealth Management increased its holdings in shares of Amneal Pharmaceuticals by 66.6% in the fourth quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock valued at $32,000 after purchasing an additional 1,023 shares during the last quarter. Intech Investment Management LLC increased its holdings in shares of Amneal Pharmaceuticals by 1.2% in the fourth quarter. Intech Investment Management LLC now owns 97,573 shares of the company’s stock valued at $1,229,000 after purchasing an additional 1,159 shares during the last quarter. Hsbc Holdings PLC increased its holdings in shares of Amneal Pharmaceuticals by 1.6% in the fourth quarter. Hsbc Holdings PLC now owns 101,945 shares of the company’s stock valued at $1,297,000 after purchasing an additional 1,569 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Amneal Pharmaceuticals by 2.4% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 68,137 shares of the company’s stock valued at $859,000 after purchasing an additional 1,582 shares during the last quarter. Finally, Comerica Bank increased its holdings in shares of Amneal Pharmaceuticals by 56.1% in the fourth quarter. Comerica Bank now owns 4,690 shares of the company’s stock valued at $59,000 after purchasing an additional 1,685 shares during the last quarter. Institutional investors and hedge funds own 31.82% of the company’s stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.